Page 119 - 80_01

Class
I
phosphoinositide
3-­-kinases
in
immunity…

28.
Yap,
T.
A.;
Garrett,
M.
D.;
Walton,
M.
I.;
Raynaud,
F.;
de
Bono,
J.
S.;
&
Workman,
P.
Targeting

the
PI3K-­-AKT-­-mTOR
pathway:
progress,
pitfalls,
and
promises.
Curr
Opin
Pharmacol
8,

393-­-412
(2008).

29.
Chi,
H.
Regulation
and
function
of
mTOR
signalling
in
T
cell
fate
decisions.
Nat
Rev
Immunol

12,
325-­-338
(2012).

30.
Dodson,
L.
F.;
Boomer,
J.
S.;
Deppong,
C.
M.;
Shah,
D.
D.;
Sim,
J.;
Bricker,
T.
L.;
Russell,
J.
H.;
&

al.
Targeted
kock-­-in
mice
expressing
mutations
of
CD28
reveal
an
essential
pathway
for

costimulation.
Mol
Cell
Biol
29,
3710-­-3721
(2009).

31.
Dragoi,
A.-­-M.;
Fu,
X.;
Ivanov,
S.;
Zhang,
P.;
Sheng,
L.;
Wu,
D.;
Li,
G.
C.;
&
al.
DNA-­-PKcs,
but
not

TLR9,
is
required
for
activation
of
Akt
by
CpG-­-DNA.
EMBO
J
24,
779-­-789
(2005).

32.
Bozulic,
L.;
Surucu,
B.;
Hynx,
D.;
&
Hemmings,
B.
A.
PKBa/Akt1
acts
downstream
of
DNA-­-PK

in
the
DNA
double-­-strand
break
response
and
promotes
survival.
Mol
Cell
30,
203-­-213

(2008).

33.
Finlay,
D.;
&
Cantrell,
D.
A.
Phosphoinositide
3-­-kinase
and
the
mammalian
target
of

rapamycin
pathways
control
T
cell
migration.
Ann
N
Y
Acad
Sci
1183,
149-­-157
(2010).

34.
Bustelo,
X.
R.
Regulatory
and
signaling
properties
of
the
Vav
family.
Mol
Cell
Biol
20,
1461-­-
1477
(2000).

35.
Smith,
C.
I.
E.;
Islam,
T.
C.;
Mattsson,
P.
T.;
Mohamed,
A.
J.;
Nore,
B.
F.;
&
Vihinen,
M.
The
Tec

family
of
cytoplasmic
tyrosine
kinases:
mammalian
Btk,
Bmx,
Itk,
Tec,
Txk
and
homologs

in
other
species.
BioEssays
23,
436-­-446
(2001).

36.
Readinger,
J.
A.;
Mueller,
K.
L.;
Venegas,
A.
M.;
Horai,
R.;
&
Schwartzberg,
P.
L.
Tec
kinases

regulate
T-­-lymphocyte
development
and
function:
new
insights
into
the
roles
of
Itk
and

Rlk/Txk.
Immunol
Rev
228,
93-­-114
(2009).

37.
Lee,
K.-­-Y.;
D'Acquisto,
F.;
Hayden,
M.
S.;
Shim,
J.-­-H.;
&
Ghosh,
S.
PDK1
nucleates
T
cell

receptor-­-induced
signaling
complex
for
NF-­-?B
activation.
Science
308,
114-­-118
(2005).

38.
Nirula,
A.;
Ho,
M.;
Phee,
H.;
Roose,
J.;
&
Weiss,
A.
Phosphoinositide-­-dependent
kinase
1

targets
protein
kinase
A
in
a
pathway
that
regulates
interleukin
4.
J
Exp
Med
203,
1733-­-
1744
(2006).

39.
Zhao,
L.;
&
Vogt,
P.
K.
Class
I
PI3K
in
oncogenic
cellular
transformation.
Oncogene
27,
5486-­-
5496
(2008).

40.
Samuels,
Y.;
&
Waldman,
T.
Oncogenic
mutations
of
PIK3CA
in
human
cancers.
In
Rommel,

C.;
Vanhaesebroeck,
B.;
&
Vogt,
P.
K.,
Editors.
In
Phosphoinositide
3-­-kinase
in
Health
and

Disease;
Springer
Berlin
Heidelberg,
2010;
p.
21-­-41.

41.
Gabelli,
S.;
Huang,
C.-­-H.;
Mandelker,
D.;
Schmidt-­-Kittler,
O.;
Vogelstein,
B.;
&
Amzel,
L.
M.

Structural
effects
of
oncogenic
PI3Ka
mutations.
In
Rommel,
C.;
Vanhaesebroeck,
B.;
&

Vogt,
P.
K.,
Editors.
In
Phosphoinositide
3-­-kinase
in
Health
and
Disease;
Springer
Berlin

Heidelberg,
2010;
p.
43-­-53.

42.
Samuels,
Y.;
Wang,
Z.;
Bardelli,
A.;
Silliman,
N.;
Ptak,
J.;
Szabo,
S.;
Yan,
H.;
&
al.
High

frequency
of
mutations
of
the
PIK3CA
gene
in
human
cancers.
Science
304,
554
(2004).

43.
Sun,
M.;
Hillmann,
P.;
Hofmann,
B.
T.;
Hart,
J.
R.;
&
Vogt,
P.
K.
Cancer-­-derived
mutations
in

the
regulatory
subunit
p85a
of
phosphoinositide
3-­-kinase
function
through
the
catalytic

subunit
p110a
Proc
Natl
Acad
Sci
USA
107,
15547-­-15552
(2010).

44.
Soler,
A.;
Serra,
H.;
Pearce,
W.;
Angulo,
A.;
Guillermet-­-Guibert,
J.;
Friedman,
L.
S.;
Viñals,
F.;

&
al.
Inhibition
of
the
p110a
isoform
of
PI
3-­-kinase
stimulates
nonfunctional
tumor

angiogenesis.
J
Exp
Med
210,
1937-­-1945
(2013).

45.
Angulo,
I.;
Vadas,
O.;
Garçon,
F.;
Banham-­-Hall,
E.;
Plagnol,
V.;
Leahy,
T.
R.;
Baxendale,
H.;
&

al.
Phosphoinositide
3-­-kinase
d
gene
mutation
predisposes
to
respiratory
infection
and

airway
damage.
Science
342,
866-­-871
(2013).

46.
Fransson,
S.;
Uv,
A.;
Eriksson,
H.;
Andersson,
M.
K.;
Wettergren,
Y.;
Bergo,
M.;
&
Ejeskar,
K.

p37d
is
a
new
isoform
of
PI3K
p110d
that
increases
cell
proliferation
and
is
overexpressed

in
tumors.
Oncogene
30,
Adv.
Online
Pub.
(2011).

47.
Papakonstanti,
E.
A.;
Ridley,
A.
J.;
&
Vanhaesebroeck,
B.
The
p110d
isoform
of
PI
3-­-kinase

negatively
controls
RhoA
and
PTEN.
EMBO
J
26,
3050-­-3061
(2007).

48.
Tzenaki,
N.;
Andreou,
M.;
Stratigi,
K.;
Vergetaki,
A.;
Makrigiannakis,
A.;
Vanhaesebroeck,
B.;

&
Papakonstanti,
E.
A.
High
levels
of
p110d
PI3K
expression
in
solid
tumor
cells
suppress

PTEN
activity,
generating
cellular
sensitivity
to
p110d
inhibitors
through
PTEN
activation.

FASEB
J
26,
2498-­-2508
(2013).

117